D. Euan MacIntyre
Technik-/Wissenschafts-/F&E-Leiter bei Galleon Pharmaceuticals, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| James C. Mannion | M | - |
Galleon Pharmaceuticals, Inc.
 Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA. | 21 Jahre |
| Robert Booth | M | 70 |
Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA. | - |
| Chris Mirabelli | M | 69 |
Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA. | - |
| Chris Christoffersen | M | 86 |
Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA. | - |
| Thomas Dietz | M | 60 |
Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA. | - |
| James F. McLeod | M | - |
Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA. | - |
| Ralph Christofferson | M | - |
Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Dinesh Patel | M | 67 |
Arête Therapeutics, Inc.
 Arête Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Arête Therapeutics, Inc. develops and commercializes molecule drugs to treat cardiovascular and inflammatory diseases. It focuses on developing AR9281, an orally-administered compound that inhibits s-EH (soluble epoxide hydrolase), an enzyme that plays a key role in the metabolism of arachidonic acid. It also focuses on testing various back-up candidates as additional first-in-class anti-hypertensive plus agents. The company was founded in 2003 and is headquartered in Hayward, CA. | 2 Jahre |
| Yi-Xin Wang | M | - |
Arête Therapeutics, Inc.
Arête Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Arête Therapeutics, Inc. develops and commercializes molecule drugs to treat cardiovascular and inflammatory diseases. It focuses on developing AR9281, an orally-administered compound that inhibits s-EH (soluble epoxide hydrolase), an enzyme that plays a key role in the metabolism of arachidonic acid. It also focuses on testing various back-up candidates as additional first-in-class anti-hypertensive plus agents. The company was founded in 2003 and is headquartered in Hayward, CA. | 1 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 9 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- D. Euan MacIntyre
- Persönliches Netzwerk